microRNA-146a: A Biomarker for Epileptogenesis, Epilepsy Prognosis, and Treatment Resistance
Zachary O. Dent1, Liam Chen2, *
Identifiers and Pagination:Year: 2023
E-location ID: e187531832212230
Publisher ID: e187531832212230
Article History:Received Date: 1/6/2022
Revision Received Date: 18/11/2022
Acceptance Date: 25/11/2022
Electronic publication date: 20/01/2023
Collection year: 2023
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recently, more attention has been paid to identifying biomarkers for epilepsy to direct a more personalized treatment strategy, especially for patients who suffer from drug-resistant epilepsy which carries a much poorer prognosis. microRNA has emerged as an important and diverse type of biomarker that can participate in metabolic and cellular processes of the disease and, importantly, can be detected in patient’s serum. In this short review, we compile state-of-the-art evidence regarding miRNA-146a, a novel biomarker that shows high potential for studying epileptogenesis, monitoring disease progression, evaluating treatment response, and may even function as a therapeutic target given its role in the process of neuroinflammation.